Home › Compound Library › MDA (3,4-Methylenedioxyamphetamine)

MDA (3,4-Methylenedioxyamphetamine)

Empathogenoral · inferred

Amphetamine-class empathogen and psychedelic ("Sally"). Active metabolite of MDMA but also used directly. More potent serotonin releaser and significantly more neurotoxic than MDMA — directly destroys serotonergic nerve terminals in animal studies with damage lasting months to years. Effects last ~8 hours (longer than MDMA). Half-life ~10h. CYP2D6 polymorphism affects metabolism.

Projected serum levels — 100 mg, as needed (shown daily)

MDA (3,4-Methylenedioxyamphetamine)
MDA (3,4-Methylenedioxyamphetamine) modeled serum levels, 100 mg as needed (shown daily) over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 25 50 75 100 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1

Maintenance schedule: 100 mg as needed (shown daily) (oral).

Modeled steady state after ~1 days: peak ≈ 80.9 mg, trough ≈ 10.0 mg body load. Population-based estimate over 15 days for a 100 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Empathogen
Route modeled
Oral
Model confidence
inferred
Half-life
7 h
Common dose
100 mg
Reference dose range
50–200 mg (single dose)
Suggested cadence
as needed (shown daily)
Validated against
100 mg oral — Cmax 0.18 mg/L at 2 h

Documented interactions

  • contraindicated
    6-APB (Benzofury / 6-(2-aminopropyl)benzofuran) + MDA (3,4-Methylenedioxyamphetamine) CYP inhibition

    MDA (3,4-Methylenedioxyamphetamine) mechanism_based of CYP2D6 predicted to change 6-APB (Benzofury / 6-(2-aminopropyl)benzofuran) AUC by ~10.00x

  • contraindicated
    Atomoxetine (Strattera) + MDA (3,4-Methylenedioxyamphetamine) CYP inhibition

    MDA (3,4-Methylenedioxyamphetamine) mechanism_based of CYP2D6 predicted to change Atomoxetine (Strattera) AUC by ~5.14x

  • contraindicated
    DOM (2,5-Dimethoxy-4-methylamphetamine / STP) + MDA (3,4-Methylenedioxyamphetamine) CYP inhibition

    MDA (3,4-Methylenedioxyamphetamine) mechanism_based of CYP2D6 predicted to change DOM (2,5-Dimethoxy-4-methylamphetamine / STP) AUC by ~10.00x

  • contraindicated
    Ibogaine + MDA (3,4-Methylenedioxyamphetamine) CYP inhibition

    MDA (3,4-Methylenedioxyamphetamine) mechanism_based of CYP2D6 predicted to change Ibogaine AUC by ~10.00x

  • contraindicated
    Metoprolol (Lopressor / Toprol-XL) + MDA (3,4-Methylenedioxyamphetamine) CYP inhibition

    MDA (3,4-Methylenedioxyamphetamine) mechanism_based of CYP2D6 predicted to change Metoprolol (Lopressor / Toprol-XL) AUC by ~5.14x

  • danger
    1P-LSD (1-Propionyl-LSD) + MDA (3,4-Methylenedioxyamphetamine) Serotonin risk

    1P-LSD (1-Propionyl-LSD) and MDA (3,4-Methylenedioxyamphetamine) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

Serum checks 235 modeled interaction pairings for mda (3,4-methylenedioxyamphetamine) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Acute effects of MDMA, MDA, lysine-MDMA, and lysine-MDA in a randomized, double-blind, placebo-controlled, crossover trial in healthy participants Holze F et al. · Neuropsychopharmacology, 2025 DOI

    Head-to-head comparison of MDA and MDMA in healthy volunteers showing MDA elimination half-life of 8.4h with qualitatively more psychedelic effects and longer duration than MDMA.

  2. The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs Green AR et al. · Pharmacological Reviews, 2003 DOI

    Landmark review establishing MDA as more neurotoxic than MDMA to serotonergic neurons, with damage to 5-HT nerve endings lasting months in rats and years in primates.

2 published studies referenced in the app, each with a plain-language summary.